Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

Presentation

Design of STEADFAST Study Evaluating TX200-TR101: A Chimeric Antigen Receptor (CAR) T Regulatory Cell Therapy for Living Donor Renal Transplant Recipients

Download PDF